Organization
The Royal Marsden Hospital
7 abstracts
2 posters
Abstract
Subcutaneous amivantamab vs intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results, including overall survival (OS), from the global, phase 3, randomized controlled PALOMA-3 trial.Org: Princess Margaret Cancer Centre, Wakayama Medical University, Wakayama, Japan, Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Jilin Cancer Hospital, Drug Development Unit, The Royal Marsden Hospital and The Institute of Cancer Research,
Abstract
Development of a novel granulocyte scoring system for use as a predictive/prognostic biomarker in patients with advanced melanoma undergoing treatment with combination immunotherapy.Org: The Royal Marsden Hospital, The Royal Marsden Hospital NHS Foundation Trust, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research,
Abstract
Phase II, single-arm, open-label study of dostarlimab monotherapy in previously untreated patients with stage II/III dMMR/MSI-H locally advanced rectal cancer.Org: Memorial Sloan Kettering Cancer Center, Sorbonne University and Saint-Antoine Hospital, Pitié Salpêtrière Hospital, Vall d’Hebron University Hospital/VHIO, Vall d’Hebron Institute of Oncology (VHIO),
Abstract
A phase 2, open-label, multicenter study investigating efficacy and safety of RP3 oncolytic immunotherapy combined with other therapies in patients with locoregionally advanced or recurrent squamous cell carcinoma of the head and neck.Org: The Institute of Cancer Research, The Royal Marsden Hospital, University of California Irvine, UPMC Hillman Cancer Center, Sarah Cannon Cancer Institute HCA Midwest Health,
Abstract
A phase 1b study of crizotinib in combination with temsirolimus in pediatric ALK- or MET-aberrated relapsed or refractory neuroblastoma (ITCC-053): Results of the phase 1 part.Org: Pfizer Global Research and Development, Institut Curie, Saint Cloud, France, University Medical Center Utrecht, Netherlands Cancer Institute, The Royal Marsden Hospital,
Abstract
Risk reclassification of endometrial cancer according to molecular profiling: UK single centre experience.Org: The Royal Marsden Hospital, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, The Royal Marsden Hospital NHS Foundation Trust, Royal Marsden Hospital and Institute of Cancer Research,
Abstract
Durable clinical outcomes in patients (pts) with advanced melanoma and progression-free survival (PFS) ≥3y on nivolumab (NIVO) ± ipilimumab (IPI) or IPI in CheckMate 067.Org: Dana-Farber Cancer Institute, Veneto Institute of Oncology IOV–IRCCS, University of Colorado Cancer Center, Aix-Marseille University CHU Timone, Maria Skłodowska-Curie National Institute of Oncology Center,